NEW YORK, Oct. 26 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the formation of their Scientific Advisory Board. They include:
Kenneth Anderson, M.D.
Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
Kraft Family Professor of Medicine, Harvard Medical School
Dr. Anderson of Dana-Farber Cancer Institute and Harvard Medical School holds the title of Kraft Family Professor of Medicine. Dr. Anderson graduated from John Hopkins Medical School, trained in internal medicine at Johns Hopkins hospital, and completed hematology and medical oncology training at Dana-Farber Cancer Institute.
Focusing on myeloma, Dr. Anderson is also the director of the Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute. Dr. Anderson is internationally known for his studies on myeloma and received the Waldenstrom's Award, the Robert A. Kyle Lifetime Achievement Award, the AACR Joseph A. Burchenal Award, and the ASH William Dameshek Prize for his pioneering work in myeloma biology and therapeutics, and is a member of the Institute of Medicine.
Keith Stewart, M.B. Ch.B., MBA
Professor of Medicine, Mayo Clinic
Dr. Stewart of the Department of Internal Medicine at the Mayo Clinic holds the rank of professor of medicine while being awarded the Vasek and Anna Maria Polak Professorship in Cancer Research. Having earned his medical degree at the Aberdeen University Medical School in the United Kingdom and a Master of Business Administration from the University of Western Ontario in Canada, Dr. Stewart's research focuses on the fundamental biological aspects and treatment of multiple myeloma.
Dr. Stewart is also a member of the Royal College of Physicians in London, a fellow of the Royal College of Physicians in Canada, specialist in hematology at th
|SOURCE Signal Genetics|
Copyright©2010 PR Newswire.
All rights reserved